We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In an application brought before the Federal Court pursuant to the Patented Medicines (Notice of Compliance) Regulations, Eli Lilly Canada Inc. (Eli Lilly) sought to prohibit the Minister of Health from issuing a Notice of Compliance (NOC) to Novopharm Ltd. (Novopharm) for a generic version of raloxifene hydrochloride until the expiry of Canadian Patent No. 2,250,191 (the ‘191 patent), which is the basis for Eli Lilly’s medicine marketed in Canada under the brand name EVISTA
